Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference

Rhea-AI Summary

Hepion Pharmaceuticals (NASDAQ: HEPA) announced that Dr. Todd Hobbs, its CMO, will present at the Q1 Investor Summit Conference on March 9, 2022, at 1:15 p.m. ET. The presentation will be accessible live and archived on their website. Hepion's lead candidate, rencofilstat, is a potent cyclophilin inhibitor currently under clinical development for non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The FDA granted Fast Track designation for rencofilstat for NASH in November 2021, with an IND application for HCC accepted in December 2021.

EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its CMO, Dr. Todd Hobbs, will present at the Q1 Investor Summit Conference on Wednesday, March 9, 2022 at 1:15 p.m. Eastern Time.

The virtual presentation will be broadcast live and archived on the Company’s website at www.hepionpharma.com under “Events” in the “Investors” section.

About Hepion Pharmaceuticals

The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was soon followed in December 2021 by the FDA’s acceptance of Hepion’s investigational new drug (IND) application for rencofilstat for the treatment of hepatocellular carcinoma (HCC).

Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to rencofilstat, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for rencofilstat to expand the company's footprint in the cyclophilin inhibition therapeutic space.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com

FAQ

When will Hepion Pharmaceuticals present at the Q1 Investor Summit Conference?

Hepion Pharmaceuticals will present at the Q1 Investor Summit Conference on March 9, 2022, at 1:15 p.m. Eastern Time.

What is the focus of Hepion Pharmaceuticals' drug rencofilstat?

Rencofilstat focuses on treating non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

What recent FDA designations has rencofilstat received?

Rencofilstat received Fast Track designation for NASH in November 2021 and had its investigational new drug (IND) application for HCC accepted in December 2021.

What technology does Hepion Pharmaceuticals use for drug development?

Hepion utilizes a proprietary AI platform called AI-POWR™ to enhance therapeutic drug development.

Where can I access the presentation by Hepion Pharmaceuticals?

The presentation can be accessed live and archived on Hepion Pharmaceuticals' website under the 'Events' section.